What are the recommended dosing, contraindications, and monitoring for metoprolol?

Metoprolol: Dosing, Contraindications, and Monitoring

For heart failure with reduced ejection fraction (HFrEF), start metoprolol succinate (CR/XL) at 12.5-25 mg once daily and uptitrate to the target dose of 200 mg once daily, doubling the dose every 2 weeks as tolerated. 1

Evidence-Based Dosing by Indication

Heart Failure with Reduced Ejection Fraction (HFrEF)

• Starting dose: Metoprolol succinate CR/XL 12.5-25 mg once daily 1, 2
• Target dose: 200 mg once daily 1, 3, 2
• Uptitration schedule: Double the dose at minimum 2-week intervals 1
• Mean dose achieved in trials: 159 mg total daily 2

Critical point: Only metoprolol succinate (CR/XL) has proven mortality benefit in heart failure—not metoprolol tartrate (immediate-release). 4, 3 The target dose of 200 mg daily for heart failure is substantially higher than doses used for hypertension (25-100 mg daily), and physicians commonly underdose due to unfamiliarity with these higher targets. 5

Acute Myocardial Infarction (Early Treatment)

• IV administration: 5 mg IV bolus over 1-2 minutes, repeated every 5 minutes for total of 15 mg 6, 7, 8
• Oral transition: Begin 25-50 mg orally every 6 hours, starting 15 minutes after last IV dose, continue for 48 hours 6, 8
• Maintenance: 100 mg twice daily thereafter 6, 7

Unstable Angina/NSTEMI

• Target resting heart rate: 50-60 beats per minute 6, 7
• Alternative oral initiation if IV not indicated: Start with lower doses (12.5 mg) and uptitrate based on tolerance 6

Absolute Contraindications

Do not administer metoprolol in the following situations: 7, 8

• Heart rate < 45-50 beats per minute (< 60 bpm in acute MI setting)
• Second- or third-degree heart block without functioning pacemaker
• Marked first-degree AV block (PR interval ≥ 0.24 seconds)
• Systolic blood pressure < 90-100 mm Hg
• Severe decompensated heart failure with signs of congestion (rales, S3 gallop, raised JVP, ascites, marked peripheral edema)
• Current or recent (within 4 weeks) acute HF exacerbation requiring hospitalization
• Cardiogenic shock or high risk for shock (Killip Class II-III with tachycardia)
• Known hypersensitivity to metoprolol or other beta-blockers

Cautions Requiring Specialist Input

• NYHA Class IV heart failure: Refer for specialist advice before initiation 1
• Asthma/severe COPD: Use cautiously with low-dose beta-1 selective agent; mild wheezing is not an absolute contraindication but requires reduced starting dose (12.5 mg) 6, 7
• Hepatic impairment: Initiate at low doses with cautious gradual titration; metoprolol levels increase substantially due to reduced first-pass metabolism 8

Monitoring Parameters

During Initiation and Uptitration

• Heart rate and blood pressure: Check at each dose increment 1
• Clinical status: Assess for symptoms, signs of congestion, body weight 1
• Blood chemistry: Check at 1-2 weeks after initiation and 1-2 weeks after reaching final target dose 1
• ECG monitoring: Continuous during IV administration 6, 7

Ongoing Maintenance

• Monitor for worsening symptoms (dyspnea, fatigue, edema, weight gain)
• Daily weights recommended (patients should increase diuretic if weight increases by 1.5-2.0 kg over 2 days) 1

Problem-Solving During Uptitration

If increasing congestion develops:

• Double diuretic dose first
• If inadequate response, halve beta-blocker dose 1

If marked fatigue or bradycardia (HR < 50 bpm with symptoms):

• Halve beta-blocker dose
• Review other heart rate-slowing medications (digoxin, amiodarone, diltiazem) 1

If serious deterioration:

• Halve dose or temporarily stop (rarely necessary)
• Seek specialist advice 1

Critical Clinical Pearls

1. Target doses matter: Lower doses provide less benefit than target doses, and there is little evidence that "medium-range" doses approximate the survival benefits of target doses. 5 Some beta-blocker is better than none, but aggressive uptitration should be the goal.

2. Blood pressure concerns are often overestimated: The most dramatic BP drops occur with the initial low starting dose, not with subsequent increments. 5

3. Temporary worsening is expected: 20-30% of patients experience temporary symptomatic deterioration during initiation/uptitration, which can usually be managed by adjusting other medications without stopping the beta-blocker. 1

4. Symptomatic improvement is delayed: Benefits may take 3-6 months or longer to manifest. 1

5. Drug interactions: Potent CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion) increase metoprolol exposure 4-6 fold and should be avoided; moderate inhibitors (citalopram, escitalopram, duloxetine) cause 2-3 fold increases and require dose reduction. 9

6. Formulation matters: Metoprolol succinate (CR/XL) provides more consistent 24-hour heart rate control than immediate-release tartrate and is the only formulation with proven mortality benefit in heart failure. 4, 3, 10